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Introduction
Ovarian cancer is the second most common gynecologic 
malignancy, with the highest mortality rate [1]. Because it is 
difficult to detect ovarian cancer at an early stage, it is usu-
ally not diagnosed until the advanced stage. As with most 
cancers, ovarian cancer has a high 5-year relative survival 
rate (92.6%) if detected early [2]. Ovarian cancer is surgically 
staged, and an optimal staging operation is required to de-
termine the exact stage, treatment plan, and prognosis. The 
surgical methods for staging ovarian cancer include total hys-
terectomy, bilateral salpingo-oophorectomy, pelvic and para-
aortic lymphadenectomy, omentectomy, peritoneal biopsy, 
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and peritoneal washing for cytology [3,4].
Recently, many gynecologic surgeries have been performed 
using a minimally invasive approach compared with the previ-
ous invasive approaches, with improved surgical outcomes 
such as better cosmetic results, less postoperative pain and in-
traoperative blood loss, and shorter hospital stay. In particular, 
single-port laparoscopy using a single incision in the umbilicus 
maximizes the advantages of conventional laparoscopy [5-8].
There have been few studies on single-port laparoscopy for 
ovarian cancer staging [9,10]. Staging laparotomy is still the 
traditional method, and minimally invasive staging surgery is 
not widely available owing to limitations in exploring the full 
extent of the peritoneal surface, port-site metastasis, and a 
higher incidence of intraoperative tumor rupture [7,11,12]. 
The aims of this study were to introduce and evaluate the 
safety and feasibility of single-port laparoscopic surgical stag-
ing (SPLS), and to compare its perioperative surgical and sur-
vival outcomes with those of staging laparotomy in patients 
with early ovarian cancer.
Materials and methods
1. Data collection
We retrospectively reviewed the medical records of patients 
who underwent staging surgery for suspected ovarian cancer 
between January 1, 2014 and December 31, 2018 at Yonsei 
Cancer Center, Severance Hospital, Yonsei University Col-
lege of Medicine in Seoul, Korea. During the study period, a 
total of 1,126 patients were diagnosed with ovarian cancer 
and underwent surgical staging, of whom 725 patients un-
derwent staging laparotomy and 401 patients underwent 
staging laparoscopy. In the staging laparoscopy group, 149 
patients underwent SPLS. There were 40 patients in the SPLS 
group and 41 patients in the laparotomy group who were 
diagnosed with International Federation of Gynecology and 
Obstetrics (FIGO) stage I ovarian cancer after surgical stag-
ing. Patients found to have metastatic cancers or borderline 
tumors in the final pathology were excluded. Only patients 
who underwent primary surgical staging at our hospital were 
included in this study (Fig. 1).
The collected data included patient age, body mass index 
(BMI), pelvic adhesion, tumor size confirmed with preopera-
tive imaging, tumor histology and grade, preoperative clinical 
stage, FIGO stage, operation time, estimated blood loss, he-
moglobin change, transfusion rate, harvested lymph nodes 
(LNs), length of hospital stay, intraoperative and postopera-
tive complications, postoperative pain scores (immediately 
postoperation, postoperative day 1, and postoperative day 3), 
postoperative adjuvant chemotherapy, and recurrence rate. 
Fig. 1. Flowchart of patient selection. SPLS, single-port laparoscopic surgical staging; FIGO, International Federation of Gynecology and 
Obstetrics.
Exclusion:
- No carcinoma, 33
- No primary ovarian cancer, 2
- FIGO stage >I, 56
- No primary staging surgery, 18
401 patients who underwent the
staging laparoscopy
1,126 patients who underewent staging operation due to the suspected ovarian cancer
40 patients who diagnosed with FIGO
stage I after the staging surgery
149 patients who underwent the
SPLS
725 patients who underwent the
staging laparotomy
41 patients who diagnosed with FIGO
stage I after the staging surgery
Exclusion:
- No carcinoma, 18
- No primary ovarian cancer, 3
- FIGO stage >I, 536
- No primary staging surgery, 127
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Operative time was defined as the time from skin incision to 
completion of skin closure. Pain was evaluated using the nu-
meric pain intensity scale (NPIS). Intraoperative complications 
were defined as adjacent organ or vessel injury, and wound 
complications were defined as wound discharge, dehiscence, 
and operative wound herniation. The number of cycles of 
postoperative adjuvant chemotherapy was compared. Fol-
low-up duration was defined as the number of months from 
the operation date to the last follow-up date.
2. Surgical techniques
1) Single-port laparoscopic surgical staging
Under general anesthesia, the patient was placed in the 
lithotomy position and the skin was prepared in the usual 
manner. A uterine manipulator was used. As in our previous 
studies, after a 1.2–1.5 cm vertical intraumbilical skin incision 
with a 1.5–2.0 cm rectus fasciotomy was made, an Alexis 
wound retractor (Applied Medical, Rancho Santa Margarita, 
CA, USA) was inserted through the umbilical incision and a 
surgical glove was combined with the Alexis wound retractor 
for a single-port entry system (Fig. 2A). Subsequently, the ab-
dominal cavity was filled with CO2 gas and the patient was 
placed in the Trendelenburg position [13,14].
After the pelvic and abdominal cavities were thoroughly 
explored, peritoneal washing cytology samples were ob-
tained first. Thereafter, each procedure (e.g., hysterectomy, 
salpingo-oophorectomy, lymphadenectomy, omentectomy, 
peritonectomy, and appendectomy) was performed using 
bipolar or monopolar electrocautery and LigaSure (Covidien 
Valleylab, Boulder, CO, USA) or the Thunderbeat system 
(Olympus Medical Systems Corp., Tokyo, Japan) [4].
To avoid spilling into the intraperitoneal cavity, ovarian 
tumors were removed using a laparoscopic tissue retrieval 
bag (LapBag; Sejong Medical Co., Ltd., Seoul, Korea) (Fig. 2B 
and C). In the case of large tumors (longest diameter ≥15 cm), 
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SW Kim’s technique was used to insert the tumors in a re-
trieval bag [15], the bag was retracted through the umbili-
cus, and the tumor was removed by aspirating and cutting 
it inside the bag. After hemostasis and irrigation, the Alexis 
wound retractor was removed and the umbilical fascia and 
subcutaneous layer were approximated with 1–0 and 2–0 
Vicryl sutures (Ethicon, Piscataway, NJ, USA) [13,14].
2) Staging laparotomy
The preoperative preparation, surgical procedures, and 
postoperative management were essentially the same as for 
SPLS, except for a low midline or extended midline incision 
and nonuse of CO2 gas.
3. Statistical methods
Statistical analysis was performed using SPSS version 25 (IBM, 
Armonk, NY, USA). A P-value of <0.05 was considered statis-
tically significant. Categorical variables are presented as fre-
quencies and percentages, and the Pearson χ2 test was used 
to evaluate differences between proportions. For continuous 
variables, medians and ranges of variables are presented, 
and the Mann-Whitney U test was performed. Kaplan-Meier 
estimates were used to evaluate differences in time to recur-
rence (Fig. 3A and B), and propensity score matching was 
used to adjust for selection bias (Supplementary Table 1) [16-18].
Results
In total, 81 patients who underwent surgical staging for early 
ovarian cancer were selected (40 SPLS and 41 laparotomy). 
In the SPLS group, 1 patient (2.5%) was converted to staging 
laparotomy because of a large tumor and 3 patients (7.5%) 
required an additional port.
The patient characteristics are shown in Table 1. The me-
dian age of patients in the SPLS group was younger than 
that of patients in the laparotomy group (46.4 [15–86] vs. 
53.8 [19–61] years, P=0.005). There was no significant dif-
ference in median BMI (24.0 [15.0–36.8] vs. 23.2 [16.7–32.9] 
kg/m2, P=0.461) or pelvic adhesion rate (50.0% vs. 39.0%, 
P=0.320). The median tumor size was 11 cm in the SPLS 
group and 15.4 cm in the laparotomy group (P=0.001). The 
most common tumor histology type in the SPLS group was 
mucinous adenocarcinoma (30.0%), followed by clear cell 
carcinoma (25.0%), sex cord-stromal tumor (12.5%), and 
endometrioid adenocarcinoma (10.0%). In the laparotomy 
group, mucinous (22.0%) and endometrioid (22.0%) ad-
enocarcinomas were the most common histologic types, 
followed by serous adenocarcinoma (19.5%) and clear cell 
carcinoma (19.5%). The tumor grade was not significantly 
different between the 2 groups (SPLS group vs. laparotomy 
group, grade 1: 27.5% vs. 17.1%, grade 2: 20.0% vs. 
34.1%, grade 3: 25.0% vs. 24.4%; P=0.464). With respect 
to the FIGO stage, stage IA was the most common stage in 
both groups (70.0% and 39.0% in the SPLS and laparotomy 
groups, respectively), and the SPLS group had more stage 
IA cases (P=0.010). FIGO stage IC1 constituted 5.0% and 
19.5%, IC2 20.0% and 22.0%, and IC3 2.5% and 19.5% in 
the SPLS and laparotomy groups, respectively.
Of 149 patients who underwent SPLS for suspected ovar-
Fig. 3. Comparison of survival curves between single-port laparoscopic surgical staging (SPLS) and staging laparotomy. (A) Before pro-
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ian cancer, 96 patients were finally diagnosed with ovarian 
cancer after the surgery. Table 2 shows the preoperative 
clinical stage and postoperative FIGO stage of patients who 
were finally diagnosed with ovarian cancer. Fourteen patients 
(14.6%) were upstaged from preoperative clinical stage I to 
postoperative FIGO stage II to IV (FIGO stage II: 10 patients, 
stage III: 3 patients, and stage IV: 1 patient).
Furthermore, we performed propensity score matching to 
minimize the difference in clinical characteristics between the 
two groups. The number of patients after propensity score 
matching decreased to 21 in each group, and the patient 
characteristics are summarized in Supplementary Table 1.
There was no significant difference between the 2 groups 
in terms of surgical procedures (Table 3). The number of 
harvested LNs (14.3 vs. 21.0, P=0.145), total operation time 
(201.4 vs. 203.0 minutes, P=0.806), and postoperative he-
moglobin change (2.1 vs. 2.2 g/dL, P=0.981) did not differ 
between the SPLS and laparotomy groups. The estimated 
blood loss was smaller in the SPLS group (median: 102 mL, 
range: 10–1,100 mL) than in the laparotomy group (median: 
371.5 mL, range: 10–1,870 mL) (P<0.001). Moreover, the 
intraoperative transfusion rate was lower in the SPLS group 
(1/40 [2.5%] vs. 8/41 [19.5%], P=0.015). The SPLS group 
showed lower postoperative pain score (immediately postop-
eration: 5.2 [2–7] vs. 6.0 [2–9], P=0.003; postoperative day 
1: 3.7 [2–8] vs. 4.9 [2–10], P = 0.004; postoperative day 3: 
2.9 [1–7] vs. 3.5 [2–7], P=0.017) and shorter postoperative 
hospital stay (5 vs. 9.5 days, P<0.001). The intraoperative 
major complication rate was similar between groups (2.5% 
vs. 4.9%, P=0.571). The SPLS group had 1 case of vascular 
injury, and the laparotomy group had 2 cases of bowel injury. 
There were no wound complications such as wound dehis-
cence or umbilical hernia in the SPLS group, whereas wound 
discharge was observed in 2 patients in the laparotomy 
group.
The adjuvant chemotherapy rate was lower in the SPLS 
group than in the laparotomy group (40.0% vs. 75.6%, 
P=0.001) (Table 4). The median number of chemotherapy 
cycles was similar in the two groups (5.1 vs. 5.3 cycles, 
P=0.426). The SPLS group showed a longer time to chemo-
therapy after the surgery (17.3 vs. 15.3 days, P=0.031).
Table 2. Comparison of preoperative clinical stage and postop-
erative surgical stage in patients who were diagnosed with ovarian 
cancer after single-port laparoscopic surgical staging (n=96)
Postoperative FIGO stage
I II III IV Total
Preoperative 
clinical stage
I 40 10 3 0 53
II 0 4 0 0 4
III 0 0 24 1 25
IV 0 0 0 14 14
Total 40 14 27 15
FIGO, 2014 International Federation of Gynecology and Obstetrics.
Table 1. Patient characteristics in the single-port laparoscopic 





Age (yr) 46.4 (15–86) 53.8 (19–61) 0.005a)
BMI (kg/m2) 24 (15.0–36.8) 23.2 (16.7–32.9) 0.461a)
Pelvic adhesion 20 (50) 16 (39.0) 0.320b)
Tumor size (cm) 11 (2.5–28) 15.4 (6–40) 0.001a)
FIGO stage 0.010b)
IA 28 (70.0) 16 (39.0)
IB 0 (0.0) 0 (0.0)
IC1 2 (5.0) 8 (19.5)
IC2 8 (20.0) 9 (22.0)
IC3 1 (2.5) 8 (19.5)
Unknown 1 (2.5) 0 (0.0)
Histology 0.111b)
Serous 3 (7.5) 8 (19.5)
Mucinous 12 (30.0) 9 (22.0)
Seromucinous 2 (5.0) 3 (7.3)
Endometrioid 4 (10.0) 9 (22.0)
Clear cell 10 (25.0) 8 (19.5)
Malignant germ 
cell
1 (2.5) 3 (7.3)
Sex cord-stromal 5 (12.5) 1 (2.4)
Others 3 (7.5) 0 (0.0)
Tumor grade 0.464b)
Grade 1 11 (27.5) 7 (17.1)
Grade 2 8 (20.0) 14 (34.1)
Grade 3 10 (25.0) 10 (24.4)
N/A 11 (27.5) 10 (24.4)
Data are presented as median (range) or number (%).
BMI, body mass index; N/A, not applicable; FIGO, 2014 International 
Federation of Gynecology and Obstetrics.
a)Calculated using the Mann-Whitney nonparametric test; b)Calcu-
lated using the χ2 parametric test.
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Table 3. Surgical outcomes of single-port laparoscopic surgical staging (SPLS, n=40) and staging laparotomy (n=41)





Hysterectomy 30 (75.0) 33 (80.5)
Unilateral salpingo-oophorectomy 15 (37.5) 3 (7.3)
Bilateral salpingo-oophorectomy 24 (60.0) 38 (92.7)
Lymphadenectomy 34 (85.0) 39 (95.1)
Omentectomy 32 (80.0) 37 (90.2)
Appendectomy 6 (15.0) 27 (65.9)
Peritonectomy 14 (35.0) 11 (26.8)
Others 7 (17.5) 7 (17.1)
Harvested LNs 14.3 (0–46) 21.1 (0–72) 0.145a)
Operation time (min) 201.4 (92–412) 203.0 (92–521) 0.806a)
EBL (mL) 102 (10–1,100) 371.5 (10–1,870) <0.001a)
Hb changes (g/dL) 2.1 (0.3–4.2) 2.2 (0.7–4.1) 0.981a)
Intraoperative transfusion 1 (2.5) 8 (19.5) 0.015b)
Pain score (NPIS)
Immediately post-operation 5.2 (2–7) 6.0 (2–9) 0.003a)
POD#1 3.7 (2–8) 4.9 (2–10) 0.004a)
POD#3 2.9 (1–7) 3.5 (2–7) 0.017a)
Postoperative hospital stay (day) 5 (2–9) 9.5 (5–20) <0.001a)
Intraoperative complications 1 (2.5) 2 (4.9) 0.571b)
Bowel injury 0 (0.0) 2 (4.9)
Vessel injury 1 (2.5) 0 (0.0)
Wound complications 0 (0.0) 2 (4.9) 0.157b)
Wound discharge 0 (0.0) 2 (4.9)
Hernia 0 (0.0) 0 (0.0)
Data are presented as median (range) or number (%).
LN, lymph node; EBL, estimated blood loss; Hb, hemoglobin; NPIS, numeric pain intensity scale; POD, postoperative day.
a)Calculated using the Mann-Whitney nonparametric test; b)Calculated using the χ2 parametric test.





Adjuvant chemotherapy 16 (40.0) 31 (75.6) 0.001b)
Cycles of chemotherapy 5.1 (3–6) 5.3 (1–8) 0.426a)
Time to chemotherapy (day) 17.3 (7–31) 15.3 (6–25) 0.031a)
Data are presented as median (range) or number (%).
SPLS, single-port laparoscopic surgical staging.
a)Calculated using the Mann-Whitney nonparametric test; b)Calculated using the χ2 parametric test.
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The median follow-up time was 35.8 months (range, 
15–72 months) in the SPLS group and 48.2 months (range, 
10–74 months) in the laparotomy group. There was no sig-
nificant difference in recurrence rate (1/40 [2.5%] vs. 2/41 
[4.9%], P=0.571). The values for progression-free survival 
were compared using Kaplan-Meier survival curves, and no 
significant difference was found between the two groups 
in all patients (P=0.945) (Fig. 3A) and after propensity score 
matching (P=0.594) (Fig. 3B). There were no deaths in either 
group during the study period.
Discussion
Many studies have compared open surgery and laparoscopic 
surgery in gynecology. Furthermore, several studies have 
compared conventional laparoscopy using multiple ports and 
laparotomy in ovarian cancer [9,18,19-21]. However, no pre-
vious study has compared single-port laparoscopic surgery 
and laparotomy in ovarian cancer, although several studies 
have compared single-port and multiport laparoscopic sur-
gery for benign gynecologic diseases [13,22]. Therefore, this 
study is the first to investigate the feasibility of single-port 
laparoscopic surgery by comparing SPLS and staging lapa-
rotomy in early ovarian cancer.
According to our results, SPLS has several advantages in 
terms of surgical outcomes, such as lower estimated blood 
loss, lower transfusion rate, less postoperative pain, and 
shorter postoperative hospital stay, while showing no signifi-
cant differences in survival outcomes. Less blood loss is well 
known as one of the main advantages of minimally invasive 
surgery. In this study, there was less blood loss in the SPLS 
group than in the laparotomy group; however, the change 
in hemoglobin after surgery did not differ between the 
2 groups. This may be attributed to the increased transfusion 
rate during surgery in the staging laparotomy group. There 
were no significant differences in perioperative complications 
and postoperative wound complications.
The patients’ BMI and pelvic adhesion did not significantly 
affect the surgical methods used in this study. However, tu-
mor size is usually a major concern in selecting laparoscopic 
surgery, especially in patients with possible malignant ovarian 
tumors. If the ovarian tumor is too large, it is usually difficult 
to remove safely, which is a limitation to performing laparo-
scopic surgery. Thus, most surgeons usually prefer laparoto-
my for large ovarian tumors. Nevertheless, there have been 
several attempts to perform minimally invasive surgeries even 
with large ovarian tumors, and we previously reported a 
technique for removing large ovarian tumors without aspira-
tion or rupture in single-port laparoscopic surgery [15]. By 
using a large endoscopic bag, such as a 30×30 cm or 50×50 
cm endoscopic tissue retrieval bag, huge ovarian tumors 
could be removed without any tumor spillage or cystic fluid 
aspiration. In this study, SPLS was successfully performed in 
most patients and showed a relatively lower tumor rupture 
rate than laparotomy (5% vs. 19.5%). However, in some pa-
tients, SPLS may require an additional port or conversion to 
laparotomy, especially when the tumor has severe adhesions.
The number of patients diagnosed with FIGO stage IA 
ovarian cancer was higher in the SPLS group. Accordingly, 
the postoperative adjuvant chemotherapy rate was lower in 
the SPLS group than in the laparotomy group. This may be 
associated with the relatively larger tumor size and higher 
tumor spillage rate in the laparotomy group. Although the 
laparotomy group had more patients with higher-stage dis-
ease in this study, there was no statistically significant differ-
ence in progression-free or overall survival rates between the 
2 groups.
Our study was a retrospective study, and there may be 
some bias in the study design (i.e., review of electronic medi-
cal records). The sample size was too small to represent the 
entire population. A single surgeon performed all operations 
in the SPLS group, whereas multiple surgeons performed the 
operations in the staging laparotomy group. Each patient 
had a different duration of follow-up, and the follow-up 
period was <1 year in some patients; thus, there were insuf-
ficient data on cancer relapse or death. Further prospective 
randomized comparison studies are needed to confirm the 
safety of SPLS in terms of survival outcomes.
In conclusion, SPLS has several advantages in terms of 
blood loss, postoperative pain, and hospital stay, without 
compromising survival outcomes. SPLS, when performed by 
experienced gynecologic oncology surgeons, may be feasible 
and safe in the surgical staging of early ovarian cancer.
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